Stockreport

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference [Financial Post (Toronto, Ontario, Canada)]

ProMIS Neurosciences Inc.  (PMN) 
PDF Results indicated PMN310 was generally well-tolerated and monthly dosing can provide CSF levels adequate for target engagement Initiation of Phase 1b clinical trial i [Read more]